SAN FRANCISCO — In this Healio Video Perspective from the AAO meeting, Marco A. Zarbin, MD, PhD, FACS, discusses a post hoc analysis of faricimab vs. aflibercept in patients with DME and visual acuity of 20/50 or worse.
The post hoc analysis of the YOSEMITE and RHINE studies found similar visual acuity results between patients treated with faricimab or aflibercept but superior central subfield thickness in patients treated with faricimab at years 1 and 2, according to Zarbin.